Feel Peptides raises $3M seed to bring premium branding to peptides
What's the deal? Feel Peptides, a startup aiming to legitimise the fast-growing peptide category with pharmaceutical-grade products and luxury branding, has raised $3 million in an oversubscribed round. Co-founded by serial entrepreneur Stephen Brudzewski and Pamela Borrero, the company pulled in six times what it initially targeted last November.
Sugar CapitalDealroom has a profile for this one. Try Dealroom →, an early investor in Grüns, led the round, with Hyve VenturesDealroom has a profile for this one. Try Dealroom → joining as a significant backer. Angel investors include makeup artist Patrick Ta, plastic surgeon Ben Talei, Four Seasons Yachts chief marketing officer Angélic Vendette, and influencers Cindy Prado and Carol Chafauzer.
Feel plans to launch a personalised membership model in Q1 next year, charging $200 to $400 annually. Members will get discounted peptides — enough to recoup the fee in one or two purchases, per Brudzewski — plus access to a nurse for consultations and blood work reviews.
The company offers peptides via subcutaneous injection, nasal sprays, and sublingual formats, and is developing topical products including sunscreen and facial skincare.
Why now? The timing is no accident. The US Food and Drug Administration (FDA) is reevaluating restrictions it placed on several popular peptides in 2023, amid growing political attention under Health and Human Services secretary Robert F. Kennedy Jr. Founders and investors are racing to stake out market position before the regulatory landscape shifts.
Feel's raise follows Protocole's $6 million round announced last month, signalling strong investor appetite for peptide-focused companies at the intersection of longevity, wellness, and aesthetics.
"GLP-1 proved that when biology works, consumers show up in the tens of millions," said Brian Sugar, co-founder of Sugar Capital. "Peptides are next."
What could go wrong? Much of the consumer-facing peptide market still flows through loosely regulated online sellers, wellness clinics, and compounding pharmacies. Many peptides marketed for cognitive performance, longevity, and wellness remain lightly studied in humans. A regulatory crackdown — or disappointing clinical evidence — could undercut the category's momentum.
The signal: The peptide market is scaling fast. Grand View Research estimates global peptide therapeutics will grow from nearly $141 billion in 2025 to almost $295 billion by 2033, with North America accounting for roughly 62% of the market.
"Two single peptides, semaglutide and tirzepatide, did more than double the revenue of Anthropic and OpenAI in 2025," said Hyve Ventures' Kara La Forgia.
The GLP-1 wave proved consumers will inject themselves weekly and tell their friends. Investors are betting that peptides — spanning weight loss, cognition, and anti-ageing — are the next frontier where biology meets consumer brand-building. Feel is positioning itself as the premium, compliant alternative to the grey market.
Read more: Beauty Independent
